Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.

Park SH, Chang YH, Lee JL, Choueiri TK, Kimura G, Chung J, Masumori N, Nishimura K, Kato M, Kato H, Numakura K, Chang CH, Anai S, Tsunemori H, Chen CH, Lin J, Elfiky A, Burgents JE, Kitamura H

Open source

DOI: 10.4143/crt.2025.365
Published: 2026 Apr
Container: Cancer research and treatment
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.4143/crt.2025.365,
  title = {Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.},
  author = {Park SH and Chang YH and Lee JL and Choueiri TK and Kimura G and Chung J and Masumori N and Nishimura K and Kato M and Kato H and Numakura K and Chang CH and Anai S and Tsunemori H and Chen CH and Lin J and Elfiky A and Burgents JE and Kitamura H},
  year = {2026},
  journal = {Cancer research and treatment},
  doi = {10.4143/crt.2025.365},
  url = {https://doi.org/10.4143/crt.2025.365}
}

RIS

TY  - JOUR
TI  - Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.
AU  - Park SH
AU  - Chang YH
AU  - Lee JL
AU  - Choueiri TK
AU  - Kimura G
AU  - Chung J
AU  - Masumori N
AU  - Nishimura K
AU  - Kato M
AU  - Kato H
AU  - Numakura K
AU  - Chang CH
AU  - Anai S
AU  - Tsunemori H
AU  - Chen CH
AU  - Lin J
AU  - Elfiky A
AU  - Burgents JE
AU  - Kitamura H
PY  - 2026
JO  - Cancer research and treatment
DO  - 10.4143/crt.2025.365
UR  - https://doi.org/10.4143/crt.2025.365
ER  -

APA

SH, P., YH, C., JL, L., TK, C., G, K., J, C., N, M., K, N., M, K., H, K., K, N., CH, C., S, A., H, T., CH, C., J, L., A, E., JE, B., & H, K. (2026). Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.. Cancer research and treatment. https://doi.org/10.4143/crt.2025.365

Source records

pubmed · retrieved 2026-09-26T19:13:16.654Z